Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.61 |
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 4/20 | 0.57 |
| ▸ | ICMT | O60725 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387653 | 1.00 | CNR2 (0.61) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL19638822 | 0.83 | CNR2 (0.58) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL29385124 | 0.83 | CNR2 (0.58) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL13131369 | 0.81 | CDC25A (0.72) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL10967590 | 0.80 | CDC25A (0.66) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL5462804 | 0.80 | CDC25A (0.70) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL29388385 | 0.80 | CNR2 (0.60) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL19638754 | 0.80 | CNR2 (0.60) | CNR2CDC25ACNR1ICMT | |
| SCHEMBL29019193 | 0.78 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL29388220 | 0.76 | CNR1 (0.61) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| EP-4326252-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2024-02-28 | — | — | EP | disclosed |
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024018420-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-4196113-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics, Inc. (CA) | 2023-06-21 | — | — | EP | disclosed |
| EP-4175629-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Pike Therapeutics, Inc. (CA) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| EP-4110325-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022224184-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS, INC. (CA) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022219468-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC. 1219014 B.C. LTD. (CA) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022003623-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PIKE THERAPEUTICS, INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021214545-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS, INC. (CA) | 2021-10-28 | — | — | WO | disclosed |
| EP-3247402-A1 | COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHALER | Willinsky, Michael (CA) | 2017-11-29 | — | — | EP | disclosed |
| US-20160025753-A1 | ASSAY FOR CANNABINOIDS AND METHODS OF USE THEREOF | MICROGENICS CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160025753-A1 | ASSAY FOR CANNABINOIDS AND METHODS OF USE THEREOF | MICROGENICS CORPORATION | 2016-01-28 | — | — | US | disclosed |
| WO-2016014773-A1 | ASSAY FOR CANNABINOIDS AND METHODS OF USE THEREOF | MICROGENICS CORPORATION (US) | 2016-01-28 | — | — | WO | disclosed |